Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to ...

Skyrizi and Rinvoq sales surged 70.5% and 57.2%, while Humira dropped 50.6%. Today's manic market swings are creating the perfect setup for Matt’s next volatility trade. Get his next trade alert ...

The pharmaceutical company, whose products include immunology treatments Skyrizi and Humira, as well as anti-wrinkle drug Botox, is the latest to outline plans to bolster its U.S. presence as the ...

– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 ...

Rinvoq also performed well, growing sales 57% to $1.7 billion. Meanwhile, Humira—which is now facing biosimilar erosion on all fronts—experienced a sales drop of 50% to $1.12 billion in the ...

Analysts polled by FactSet expected $12.92 billion. Sales of Abbvie's immune-disease therapy Humira were down 51% globally at $1.12 billion, and declined even more steeply on a percentage basis in ...

In addition, folds of skin may develop itchy rashes that may be irritating. Protecting against the sun isn’t just about avoiding tanning — it’s about shielding your skin from long-term damage.